Cystatin C in HIV-infected patients: Promising but not yet ready for prime time

Nephrology Dialysis Transplantation

Volumn 27, Issue 4, 2012, Pages 1305-1313

  Gagneux Brunon, Amandine ^a,b   Mariat, Christophe ^a,b   Delanaye, Pierre ^c  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

cystatin C; glomerular filtration rate; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; TRIMETHOPRIM;

CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIETARY INTAKE; ETHNICITY; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY INJURY; LEAN BODY WEIGHT; MIXED INFECTION; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TOXOPLASMOSIS; VIRUS HEPATITIS; VIRUS LOAD;

BIOLOGICAL MARKERS; CYSTATIN C; HIV; HIV INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 84859363019     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs001     Document Type: Review

References (80)

1. UNAIDS. Report on the Global AIDS Epidemic, 2010. http://www. unaids.org.
2. Koster JC, Remedi MS, Qiu H et al. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003; 52: 1695-1700 (Pubitemid 36792459)
3. Seaberg EC, Muñoz A, Lu M et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953-960 (Pubitemid 40834939)
4. Riddler SA, Li X, Chu H et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007; 8: 280-287 (Pubitemid 46901526)
5. Schwartz EJ, Szczech LA, Ross MJ et al. Highly active antiretroviral therapy and the epidemic of HIV1 end-stage renal disease. J Am Soc Nephrol 2005; 16: 2412-2420 (Pubitemid 41725059)
6. Fernando SK, Finkelstein FO, Moore BA et al. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci 2008; 335: 89-94 (Pubitemid 351253402)
7. Overton ET, Nurutdinova D, Freeman J et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med 2009; 10: 343-350
8. Crum-Cianflone N, Ganesan A, Teneza-Mora N et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS 2010; 24: 353-360
9. Campbell LJ, Ibrahim F, Fisher M et al. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med 2009; 10: 329-336
10. Lucas GM, Lau B, Atta MG et al. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008; 197: 1548-1557 (Pubitemid 351706485)
11. Vupputuri S, Batuman V, Muntner P et al. The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am J Kidney Dis 2004; 43: 629-635 (Pubitemid 38401878)
12. Mocroft A, Kirk O, Reiss P et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-1678
13. Tordato F, Cozzi Lepri A, Cicconi P et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med 2011; 12: 4-13
14. Estrella MM, Parekh RS, Abraham A et al. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr 2010; 55: 217-220
15. Mayor AM, Dworkin M, Quesada L et al. The morbidity and mortality associated with kidney disease in an HIV-infected cohort in Puerto Rico. Ethn Dis 2010; 20: S1-163-S1-167
16. George E, Lucas GM, Nadkarni GN et al. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24: 387-394
17. Szczech LA, Hoover DR, Feldman JG et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-1206 (Pubitemid 40169320)
18. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
19. Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585 (Pubitemid 40720806)
20. Estrella MM, Fine DM. Screening for chronic kidney disease in HIVinfected patients. Adv Chronic Kidney Dis 2010; 17: 26-35
21. Stevens LA, Coresh J, Greene T et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483 (Pubitemid 43855050)
22. Stevens LA, Coresh J, Schmid CH et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406 (Pubitemid 351273480)
23. Séronie-Vivien S, Delanaye P, Piéroni L et al. Cystatin C: current position and future prospects. Clin Chem LabMed 2008; 46: 1664-1686
24. Koenig W, Twardella D, Brenner H et al. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005; 51: 321-327 (Pubitemid 40175801)
25. Peralta CA, Shlipak MG, Judd S et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305: 1545-1552
26. Menon V, Shlipak MG, Wang X et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147: 19-27 (Pubitemid 351664630)
27. Choi A, Scherzer R, Bacchetti P et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56: 872-882
28. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933-1953
29. Delanaye P, Cavalier E, Maillard N et al. La créatinine: d'hier à aujourd'hui [Creatinine: past and present]. Ann Biol Clin (Paris) 2010; 68: 531-543
30. Visnegarwala F, Shlay JC, Barry V et al. Effects of HIV infection on body composition changes among men of different racial/ethnic origins. HIV Clin Trials 2007; 8: 145-154 (Pubitemid 47121759)
31. Delpierre C, Bonnet E, Marion-Latard F et al. Impact of HIV infection on total body composition in treatment-naive men evaluated by dualenergy X-ray absorptiometry comparison of 90 untreated HIVinfected men to 241 controls. J Clin Densitom 2007; 10: 376-380 (Pubitemid 350052605)
32. McDermott AY, Terrin N, Wanke C et al. CD41 cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005; 41: 1662-1670 (Pubitemid 41691607)
33. Nahlen BL, Chu SY, Nwanyanwu OC et al. HIV wasting syndrome in the United States. AIDS 1993; 7: 183-188 (Pubitemid 23091287)
34. Cocchetto DM, Tschanz C, Bjornsson TD. Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit 1983; 5: 161-168 (Pubitemid 13065400)
35. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59: 473-485 (Pubitemid 351287950)
36. Chun HM, Fieberg AM, Hullsiek KH et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis 2010; 50: 426-436
37. Fischer MJ, Wyatt CM, Gordon K et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010; 53: 222-226
38. Jones CY, Jones CA, Wilson IB et al. Cystatin C and creatinine in an HIV cohort: the nutrition for healthy living study. Am J Kidney Dis 2008; 51: 914-924 (Pubitemid 351697573)
39. Peng S, Plank LD, McCall JL et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. Am J Clin Nutr 2007; 85: 1257-1266 (Pubitemid 46740467)
40. Mofenson LM, Brady MT, Danner SP et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIVexposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58: 1-166
41. Delanaye P, Mariat C, Cavalier E et al. Trimethoprim, creatinine and creatinine based equations. Nephron Clin Pract 2011; 119: 187-193
42. Berglund F, Killander J, Pompeius R. Effect of trimethoprimsulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802-808
43. Myre SA, McCann J, First MR et al. Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers. Ther Drug Monit 1987; 9: 161-165 (Pubitemid 17078115)
44. Maki DG, Fox BC, Kuntz J et al. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprimsulfamethoxazole, interaction with cyclosporine. J Lab Clin Med 1992; 119: 11-24
45. Odden MC, Scherzer R, Bacchetti P et al. Cystatin c level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study. Arch Intern Med 2007; 167: 2213-2219 (Pubitemid 350106741)
46. Mauss S, Berger F, Kuschak D et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther 2008; 13: 1091-1095
47. Tenstad O, Roald AB, Grubb A et al. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996; 56: 409-414 (Pubitemid 26266006)
48. Knight EL, Verhave JC, Spiegelman D et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-1421 (Pubitemid 38406982)
49. Stevens LA, Schmid CH, Greene T et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75: 652-660
50. Mathisen UD, Melsom T, Ingebretsen OC et al. Estimated GFR associates with cardiovascular risk factors independently of measured GFR. J Am Soc Nephrol 2011; 22: 927-937
51. Macdonald J, Marcora S, Jibani M et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006; 48: 712-719 (Pubitemid 44740040)
52. Kramer H, Palmas W, Kestenbaum B et al. Chronic kidney disease prevalence estimates among racial/ethnic groups: the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol 2008; 3: 1391-1397
53. Delanaye P, Mariat C, Maillard N et al. Are the creatinine-based equations accurate to estimate glomerular filtration rate in African American populations? Clin J Am Soc Nephrol 2011; 6: 906-912
54. Neuhaus J, Jacobs DR, Baker JV et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795
55. Jaroszewicz J, Wiercinska-Drapalo A, Lapinski TW et al. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther 2006; 11: 641-645 (Pubitemid 44277430)
56. Estrella MM, Parekh RS, Astor BC et al. Chronic kidney disease and estimates of kidney function in HIV infection: a cross-sectional study in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2011; 57: 380-386
57. Phillips AN, Carr A, Neuhaus J et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177-187 (Pubitemid 351535369)
58. El-Sadr WM, Lundgren JD, Neaton JD et al. CD41 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 30: 2283-2296 (Pubitemid 44837777)
59. MocroftA,Wyatt C, Szczech L et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 2009; 23: 71-82
60. Longenecker CT, Scherzer R, Bacchetti P et al. HIV viremia and changes in kidney function. AIDS 2009; 23: 1089-1096
61. Bonjoch A, Bayés B, Riba J et al. Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Res 2010; 88: 347-354
62. Ciborowski P, Kadiu I, Rozek W et al. Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology 2007; 20: 198-209 (Pubitemid 46678164)
63. Overton ET, Patel P, Mondy K et al. Cystatin C and baseline renal function among HIV-infected persons in the SUN study. AIDS Res Hum Retroviruses 2012; 28: 148-155
64. Esezobor CI, Iroha E, Oladipo O et al. Kidney function of HIVinfected children in Lagos, Nigeria: using Filler's serum cystatin Cbased formula. J Int AIDS Soc 2010; 13: 17
65. Gardner LI, Holmberg SD, Williamson JM et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 203-209 (Pubitemid 36222723)
66. Hsu C-Y, Chertow GM, Curhan GC. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int 2002; 61: 1567-1576 (Pubitemid 34437910)
67. Perkins BA, Nelson RG, Ostrander BEP et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16: 1404-1412 (Pubitemid 41716524)
68. Jaafar A, Séronie-Vivien S, Malard L et al. Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients. AIDS 2009; 23: 257-259
69. Barraclough K, Er L, Ng F et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract 2009; 111: c39-c48
70. Beringer PM, Owens H, Nguyen A et al. Estimation of glomerular filtration rate by using serum cystatin C and serum creatinine concentrations in patients with human immunodeficiency virus. Pharmacotherapy 2010; 30: 1004-1010
71. van Deventer HE, Paiker JE, Katz IJ et al. A comparison of cystatin C-and creatinine-based prediction equations for the estimation of glomerular filtration rate in black South Africans. Nephrol Dial Transplant 2011; 26: 1553-1558
72. Macisaac RJ, Tsalamandris C, Thomas MC et al. Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C-and creatinine-based methods. Diabetologia 2006; 49: 1686-1689 (Pubitemid 43848107)
73. Delanaye P, Cavalier E, Krzesinski J-M et al. Cystatin C-based equations: don't repeat the same errors with analytical considerations. Nephrol Dial Transplant 2008; 23: 1065. (Pubitemid 351767590)
74. Rule AD, Lieske JC. Cystatin C is more than GFR, and this may be a good thing. J Am Soc Nephrol 2011; 22: 795-797
75. Kwong Y-TD, Stevens LA, Selvin E et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis 2010; 56: 39-49
76. Shlipak MG, Sarnak MJ, Katz R et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060 (Pubitemid 40664306)
77. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246 (Pubitemid 46768607)
78. Kuller LH, Tracy R, Belloso W et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
79. Rodger AJ, Fox Z, Lundgren JD et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200: 973-983
80. Falasca K, Ucciferri C, Mancino P et al. Cystatin C, adipokines and cardiovascular risk in HIV infected patients. Curr HIV Res 2010; 8: 405-410